Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss

Pharmacological Research

Volumn 84, Issue , 2014, Pages 1-11

  Billes, Sonja K ^a   Sinnayah, Puspha ^b   Cowley, Michael A ^c  

^a August Scientific   (United States)

^b VICTORIA UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Bupropion; Drug interactions; Food craving; Food intake; Hypothalamus; Naltrexone; Obesity; Reward system; Weight loss

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; MELANOCORTIN; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NALTREXONE; NARCOTIC ANTAGONIST;

BODY WEIGHT; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONSTIPATION; FEEDING BEHAVIOR; FOOD CRAVING; FOOD INTAKE; HEADACHE; HUMAN; HYPOTHALAMUS; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MOOD; NAUSEA; NONHUMAN; OBESITY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; REWARD; VOMITING; WEIGHT REDUCTION; DRUG COMBINATION; DRUG EFFECTS; ENERGY METABOLISM;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DRUG THERAPY, COMBINATION; ENERGY METABOLISM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; WEIGHT LOSS;

EID: 84899883639     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.04.004     Document Type: Review

References (166)

1. D.W. Haslam, and W.P. James Obesity Lancet 366 2005 1197 1209 (Pubitemid 41393598)
2. C.L. Ogden, M.D. Carroll, M.A. McDowell, and K.M. Flegal Obesity among adults in the United States - no change since 2003-04: NCHS data brief no 1 2007 National Center for Health Statistics Hyattsville, MD
3. Health, United States With special feature on the health of young adults 2008 Centers for Disease Control and Prevention, National Center for Health Statistics Hyattsville, MD
4. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of obesity and trends in body mass index among us children and adolescents, 1999-2010 J Am Med Assoc 307 2012 483 490
5. K.M. Flegal, M.D. Carroll, B.K. Kit, and C.L. Ogden Prevalence of obesity and trends in the distribution of body mass index among us adults, 1999-2010 J Am Med Assoc 307 2012 491 497
6. Y. Wang, M.A. Beydoun, L. Liang, B. Caballero, and S.K. Kumanyika Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic Obesity (Silver Spring, MD) 16 2008 2323 2330
7. S.J. Olshansky, D.J. Passaro, R.C. Hershow, J. Layden, B.A. Carnes, and J. Brody et al. A potential decline in life expectancy in the United States in the 21st century N Engl J Med 352 2005 1138 1145 (Pubitemid 40365358)
8. M.D. Jensen, D.H. Ryan, C.M. Apovian, J.D. Ard, A.G. Comuzzie, and K.A. Donato et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society Circulation 2013 [Epub ahead of print]
9. J.C. Appolinario, J.R. Bueno, and W. Coutinho Psychotropic drugs in the treatment of obesity: what promise CNS Drugs 18 2004 629 651 (Pubitemid 39141771)
10. J.L. Colquitt, J. Picot, E. Loveman, and A.J. Clegg Surgery for obesity Cochrane Database Syst Rev 2009 CD003641
11. L.L. Ioannides-Demos, L. Piccenna, and J.J. McNeil Pharmacotherapies for obesity: past, current, and future therapies J Obes 2011 2011 179674
12. N.J. Birkmeyer, J.B. Dimick, D. Share, A. Hawasli, W.J. English, and J. Genaw et al. Hospital complication rates with bariatric surgery in Michigan J Am Med Assoc 304 2010 435 442
13. S.Z. Yanovski, and J.A. Yanovski Long-term drug treatment for obesity: a systematic and clinical review J Am Med Assoc 311 2014 74 86
14. Prescribing information: Xenical (orlistat) capsules 2013 Genentech Inc. USA
15. S. Rossner, L. Sjostrom, R. Noack, A.E. Meinders, and G. Noseda Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European orlistat obesity studygroup Obes Res 8 2000 49 61
16. L. Sjostrom, A. Rissanen, T. Andersen, M. Boldrin, A. Golay, and H.P. Koppeschaar et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European multicentre orlistat studygroup Lancet 352 1998 167 172 (Pubitemid 28327800)
17. M.H. Davidson, J. Hauptman, M. DiGirolamo, J.P. Foreyt, C.H. Halsted, and D. Heber et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial J Am Med Assoc 281 1999 235 242 (Pubitemid 29058112)
18. M.C. Fidler, M. Sanchez, B. Raether, N.J. Weissman, S.R. Smith, and W.R. Shanahan et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the blossom trial J Clin Endocrinol Metab 96 2011 3067 3077
19. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, and S. Stubbe et al. Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256
20. Prescribing information: Belviq (lorcaserin hydrochloride) tablets 2012 Eisai Inc.
21. G.A. Bray Why do we need drugs to treat the patient with obesity? Obesity 21 2013 893 899
22. K.M. Gadde, D.B. Allison, D.H. Ryan, C.A. Peterson, B. Troupin, and M.L. Schwiers et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (conquer): a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 1341 1352
23. D.B. Allison, K.M. Gadde, W.T. Garvey, C.A. Peterson, M.L. Schwiers, and T. Najarian et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (equip) Obesity 20 2012 330 342
24. Prescribing information: Qsymia (phentermine and topiramate extended-release) tablets 2013 Vivus, Inc.
25. R.F. Witkamp Current and future drug targets in weight management Pharm Res 28 2011 1792 1818
26. G.J. Morton, D.E. Cummings, D.G. Baskin, G.S. Barsh, and M.W. Schwartz Central nervous system control of food intake and body weight Nature 443 2006 289 295 (Pubitemid 44435142)
27. R.L. Leibel, M. Rosenbaum, and J. Hirsch Changes in energy expenditure resulting from altered body weight N Engl J Med 332 1995 621 628
28. A. Del Parigi, J.F. Gautier, K. Chen, A.D. Salbe, E. Ravussin, and E. Reiman et al. Mapping the brain responses to hunger and satiation in humans using positron emission tomography Ann N Y Acad Sci 967 2002 389 397 (Pubitemid 34721924)
29. G.J. Wang, N.D. Volkow, F. Telang, M. Jayne, Y. Ma, and K. Pradhan et al. Evidence of gender differences in the ability to inhibit brain activation elicited by food stimulation Proc Natl Acad Sci U S A 106 2009 1249 1254
30. A. DelParigi, K. Chen, A.D. Salbe, J.O. Hill, R.R. Wing, and E.M. Reiman et al. Persistence of abnormal neural responses to a meal in postobese individuals Int J Obes Relat Metab Disord 28 2004 370 377 (Pubitemid 38296949)
31. W. Hinkle, M. Cordell, R. Leibel, M. Rosenbaum, and J. Hirsch Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans PLoS One 8 2013 e59114
32. M. Rosenbaum, M. Sy, K. Pavlovich, R.L. Leibel, and J. Hirsch Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli J Clin Invest 118 2008 2583 2591 (Pubitemid 351949785)
33. M. Rosenbaum, H.R. Kissileff, L.E. Mayer, J. Hirsch, and R.L. Leibel Energy intake in weight-reduced humans Brain Res 1350 2010 95 102
34. M.L. Pelchat Food cravings in young and elderly adults Appetite 28 1997 103 113 (Pubitemid 27219908)
35. A.J. Hill The psychology of food craving Proc Nutr Soc 66 2007 277 285
36. A. DelParigi, K. Chen, A.D. Salbe, J.O. Hill, R.R. Wing, and E.M. Reiman et al. Successful dieters have increased neural activity in cortical areas involved in the control of behavior Int J Obes (Lond) 31 2007 440 448
37. N. Vogels, K.R. Westerterp, D.L. Posthumus, F. Rutters, and M.S. Westerterp-Plantenga Daily physical activity counts vs. structured activity counts in lean and overweight Dutch children Physiol Behav 92 2007 611 616 (Pubitemid 350016123)
38. G.J. Wang, N.D. Volkow, and J.S. Fowler The role of dopamine in motivation for food in humans: implications for obesity Expert Opin Ther Targets 6 2002 601 609 (Pubitemid 35175108)
39. J.C. Halford, E.J. Boyland, J.E. Blundell, T.C. Kirkham, and J.A. Harrold Pharmacological management of appetite expression in obesity Nat Rev Endocrinol 6 2010 255 269
40. R.D. Cone Anatomy and regulation of the central melanocortin system Nat Neurosci 8 2005 571 578 (Pubitemid 40594196)
41. M.A. Cowley, R.D. Cone, P. Enriori, I. Louiselle, S.M. Williams, and A.E. Evans Electrophysiological actions of peripheral hormones on melanocortin neurons Ann N Y Acad Sci 994 2003 175 186 (Pubitemid 36793865)
42. D. Lu, D. Willard, I.R. Patel, S. Kadwell, L. Overton, and T. Kost et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor Nature 371 1994 799 802 (Pubitemid 24333868)
43. W. Fan, B.A. Boston, R.A. Kesterson, V.J. Hruby, and R.D. Cone Role of melanocortinergic neurons in feeding and the agouti obesity syndrome Nature 385 1997 165 168 (Pubitemid 27034218)
44. C. Broberger, J. Johansen, C. Johansson, M. Schalling, and T. Hokfelt The neuropeptide y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice Proc Natl Acad Sci U S A 95 1998 15043 15048 (Pubitemid 29003753)
45. L.S. Brady, M.A. Smith, P.W. Gold, and M. Herkenham Altered expression of hypothalamic neuropeptide mrnas in food-restricted and food-deprived rats Neuroendocrinology 52 1990 441 447 (Pubitemid 20366597)
46. W. Fan, A. Voss-Andreae, W.H. Cao, and S.F. Morrison Regulation of thermogenesis by the central melanocortin system Peptides 26 2005 1800 1813 (Pubitemid 41354538)
47. T.M. Mizuno, and C.V. Mobbs Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting Endocrinology 140 1999 814 817 (Pubitemid 29058217)
48. M.A. Cowley, J.L. Smart, M. Rubinstein, M.G. Cerdan, S. Diano, and T.L. Horvath et al. Leptin activates anorexigenic pomc neurons through a neural network in the arcuate nucleus Nature 411 2001 480 484 (Pubitemid 32494394)
49. C.F. Elias, C. Aschkenasi, C. Lee, J. Kelly, R.S. Ahima, and C. Bjorbaek et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area Neuron 23 1999 775 786 (Pubitemid 29411566)
50. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 402 1999 656 660 (Pubitemid 129516334)
51. M.D. Klok, S. Jakobsdottir, and M.L. Drent The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review Obes Rev 8 2007 21 34 (Pubitemid 44952832)
52. M.A. Cowley, N. Pronchuk, W. Fan, D.M. Dinulescu, W.F. Colmers, and R.D. Cone Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat Neuron 24 1999 155 163 (Pubitemid 29466155)
53. R.D. Cone Studies on the physiological functions of the melanocortin system Endocr Rev 27 2006 736 749 (Pubitemid 44936057)
54. A.S. Liotta, J.P. Advis, J.E. Krause, J.F. McKelvy, and D.T. Krieger Demonstration of in vivo synthesis of pro-opiomelanocortin-, beta-endorphin-, and alpha-melanotropin-like species in the adult rat brain J Neurosci 4 1984 956 965 (Pubitemid 14146825)
55. R.L. Pennock, and S.T. Hentges Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons J Neurosci 31 2011 281 288
56. M.J. Kelly, M.D. Loose, and O.K. Ronnekleiv Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance Neuroendocrinology 52 1990 268 275 (Pubitemid 20260129)
57. R. Burcelin, V. Crivelli, A. Dacosta, A. Roy-Tirelli, and B. Thorens Heterogeneous metabolic adaptation of c57bl/6j mice to high-fat diet Am J Physiol Endocrinol Metab 282 2002 E834 E842
58. J. Dum, C. Gramsch, and A. Herz Activation of hypothalamic beta-endorphin pools by reward induced by highly palatable food Pharmacol Biochem Behav 18 1983 443 447 (Pubitemid 13146904)
59. P.J. Enriori, A.E. Evans, P. Sinnayah, E.E. Jobst, L. Tonelli-Lemos, and S.K. Billes et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons Cell Metab 5 2007 181 194
60. A.E. Kelley, and K.C. Berridge The neuroscience of natural rewards: relevance to addictive drugs J Neurosci 22 2002 3306 3311 (Pubitemid 37465733)
61. A.E. Kelley Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning Neurosci Biobehav Rev 27 2004 765 776 (Pubitemid 38202248)
62. R.A. Wise Brain reward circuitry: insights from unsensed incentives Neuron 36 2002 229 240 (Pubitemid 35217889)
63. R.C. Pierce, and V. Kumaresan The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30 2006 215 238 (Pubitemid 41821810)
64. G. Finlayson, N. King, and J.E. Blundell Liking vs. wanting food: importance for human appetite control and weight regulation Neurosci Biobehav Rev 31 2007 987 1002 (Pubitemid 47332618)
65. K.C. Berridge, and T.E. Robinson What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience Brain Res Brain Res Rev 28 1998 309 369 (Pubitemid 29012677)
66. B.A. Baldo, and A.E. Kelley Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding Psychopharmacology (Berl) 191 2007 439 459 (Pubitemid 46355910)
67. M.J. Glass, C.J. Billington, and A.S. Levine Opioids and food intake: distributed functional neural pathways Neuropeptides 33 1999 360 368 (Pubitemid 29530128)
68. M.J. Will, E.B. Franzblau, and A.E. Kelley Nucleus accumbens mu-opioids regulate intake of a high-fat diet via activation of a distributed brain network J Neurosci 23 2003 2882 2888 (Pubitemid 36418624)
69. C.B. Saper, T.C. Chou, and J.K. Elmquist The need to feed: homeostatic and hedonic control of eating Neuron 36 2002 199 211 (Pubitemid 35217887)
70. E. Stice, S. Spoor, J. Ng, and D.H. Zald Relation of obesity to consummatory and anticipatory food reward Physiol Behav 97 2009 551 560
71. D.M. Small Individual differences in the neurophysiology of reward and the obesity epidemic Int J Obes (Lond) 33 Suppl. 2 2009 S44 S48
72. N.D. Volkow, and R.A. Wise How can drug addiction help us understand obesity Nat Neurosci 8 2005 555 560 (Pubitemid 40594193)
73. N.M. Avena, P. Rada, and B.G. Hoebel Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake Neurosci Biobehav Rev 32 2008 20 39 (Pubitemid 350160955)
74. E. Stice, S. Spoor, C. Bohon, and D.M. Small Relation between obesity and blunted striatal response to food is moderated by taqia a1 allele Science (New York, NY) 322 2008 449 452
75. G.J. Wang, N.D. Volkow, J. Logan, N.R. Pappas, C.T. Wong, and W. Zhu et al. Brain dopamine and obesity Lancet 357 2001 354 357 (Pubitemid 32128542)
76. G.J. Wang, N.D. Volkow, P.K. Thanos, and J.S. Fowler Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review J Addict Dis 23 2004 39 53 (Pubitemid 39045340)
77. S.O. Fetissov, M.M. Meguid, T. Sato, and L.H. Zhang Expression of dopaminergic receptors in the hypothalamus of lean and obese zucker rats and food intake Am J Physiol Regul Integr Comp Physiol 283 2002 R905 R910
78. X.F. Huang, Y. Yu, K. Zavitsanou, M. Han, and L. Storlien Differential expression of dopamine d2 and d4 receptor and tyrosine hydroxylase MRNA in mice prone, or resistant, to chronic high-fat diet-induced obesity Brain Res Mol Brain Res 135 2005 150 161 (Pubitemid 40602408)
79. I.S. Farooqi, E. Bullmore, J. Keogh, J. Gillard, S. O'Rahilly, and P.C. Fletcher Leptin regulates striatal regions and human eating behavior Science (New York, NY) 317 2007 1355 (Pubitemid 47417470)
80. S. Malik, F. McGlone, D. Bedrossian, and A. Dagher Ghrelin modulates brain activity in areas that control appetitive behavior Cell Metab 7 2008 400 409 (Pubitemid 351598026)
81. D.P. Figlewicz, S.B. Evans, J. Murphy, M. Hoen, and D.G. Baskin Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat Brain Res 964 2003 107 115 (Pubitemid 36165075)
82. J.D. Hommel, R. Trinko, R.M. Sears, D. Georgescu, Z.W. Liu, and X.B. Gao et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding Neuron 51 2006 801 810 (Pubitemid 44374908)
83. R.L. Batterham, D.H. ffytche, J.M. Rosenthal, F.O. Zelaya, G.J. Barker, and D.J. Withers et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans Nature 450 2007 106 109 (Pubitemid 350070563)
84. P.K. Thanos, M. Michaelides, J.D. Gispert, J. Pascau, M.L. Soto-Montenegro, and M. Desco et al. Differences in response to food stimuli in a rat model of obesity: in-vivo assessment of brain glucose metabolism Int J Obes (Lond) 32 2008 1171 1179 (Pubitemid 351986199)
85. H.R. Berthoud Interactions between the cognitive and metabolic brain in the control of food intake Physiol Behav 91 2007 486 498
86. T.L. Horvath The hardship of obesity: a soft-wired hypothalamus Nat Neurosci 8 2005 561 565 (Pubitemid 40594194)
87. G.C. Major, E. Doucet, P. Trayhurn, A. Astrup, and A. Tremblay Clinical significance of adaptive thermogenesis Int J Obes (Lond) 31 2007 204 212 (Pubitemid 46183125)
88. S.K. Billes, and F.L. Greenway Combination therapy with naltrexone and bupropion for obesity Expert Opin Pharmacother 12 2011 1813 1826
89. R.F. Anton Naltrexone for the management of alcohol dependence N Engl J Med 359 2008 715 721
90. B.A. Johansson, M. Berglund, and A. Lindgren Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review Addiction 101 2006 491 503 (Pubitemid 43375613)
91. Prescribing information: Revia (naltrexone hydrochloride) tablets 2013 Duramed Pharmaceuticals, Inc.
92. S.J. Watson, H. Akil, Richard CWr, and J.D. Barchas Evidence for two separate opiate peptide neuronal systems Nature 275 1978 226 228 (Pubitemid 9008036)
93. A.S. Reece Hypothalamic opioid-melanocortin appetitive balance and addictive craving Med Hypotheses 76 2011 132 137
94. A. Tabarin, Y. Diz-Chaves, C. Carmona Mdel, B. Catargi, E.P. Zorrilla, and A.J. Roberts et al. Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a thrifty gene Diabetes 54 2005 3510 3516 (Pubitemid 43334343)
95. D.M. Bronstein, N.C. Day, H.B. Gutstein, K.A. Trujillo, and H. Akil Pre- and posttranslational regulation of beta-endorphin biosynthesis in the CNS: effects of chronic naltrexone treatment J Neurochem 60 1993 40 49 (Pubitemid 23006700)
96. K.D. Carr, T.H. Park, Y. Zhang, and E.A. Stone Neuroanatomical patterns of fos-like immunoreactivity induced by naltrexone in food-restricted and ad libitum fed rats Brain Res 779 1998 26 32 (Pubitemid 28039936)
97. P.K. Olszewski, M.M. Wirth, M.K. Grace, A.S. Levine, and S.Q. Giraudo Evidence of interactions between melanocortin and opioid systems in regulation of feeding Neuroreport 12 2001 1727 1730 (Pubitemid 32521495)
98. M.T. Taber, G. Zernig, and H.C. Fibiger Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens Brain Res 785 1998 24 30 (Pubitemid 28194750)
99. C. Giuliano, T.W. Robbins, P.J. Nathan, E.T. Bullmore, and B.J. Everitt Inhibition of opioid transmission at the mu-opioid receptor prevents both food seeking and binge-like eating Neuropsychopharmacology 37 2012 2643 2652
100. A. Blasio, L. Steardo, V. Sabino, and P. Cottone Opioid system in the medial prefrontal cortex mediates binge-like eating Addict Biol 2013 10.1111/adb.12033
101. S.A. Taha, E. Norsted, L.S. Lee, P.D. Lang, B.S. Lee, and J.D. Woolley et al. Endogenous opioids encode relative taste preference Eur J Neurosci 24 2006 1220 1226 (Pubitemid 44268152)
102. A.E. Kelley, E.P. Bless, and C.J. Swanson Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats J Pharmacol Exp Ther 278 1996 1499 1507 (Pubitemid 27167005)
103. M. Zhang, B.A. Gosnell, and A.E. Kelley Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens J Pharmacol Exp Ther 285 1998 908 914 (Pubitemid 28237478)
104. A.C. Shin, P.J. Pistell, C.B. Phifer, and H.R. Berthoud Reversible suppression of food reward behavior by chronic mu-opioid receptor antagonism in the nucleus accumbens Neuroscience 170 2010 580 588
105. J.D. Woolley, B.S. Lee, and H.L. Fields Nucleus accumbens opioids regulate flavor-based preferences in food consumption Neuroscience 143 2006 309 317 (Pubitemid 44755232)
106. K.B. Bonacchi, K. Ackroff, K. Touzani, R.J. Bodnar, and A. Sclafani Opioid mediation of starch and sugar preference in the rat Pharmacol Biochem Behav 2010 1 8
107. A.S. Levine, M.K. Grace, J.P. Cleary, and C.J. Billington Naltrexone infusion inhibits the development of preference for a high-sucrose diet Am J Physiol Regul Integr Comp Physiol 283 2002 R1149 R1154
108. M. Apfelbaum, and A. Mandenoff Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet Pharmacol Biochem Behav 15 1981 89 91 (Pubitemid 11083226)
109. R.B. Kanarek, W.F. Mathes, L.K. Heisler, R.P. Lima, and L.S. Monfared Prior exposure to palatable solutions enhances the effects of naltrexone on food intake in rats Pharmacol Biochem Behav 57 1997 377 381 (Pubitemid 27261436)
110. M.R. Yeomans, and R.W. Gray Selective effects of naltrexone on food pleasantness and intake Physiol Behav 60 1996 439 446 (Pubitemid 26274284)
111. M.R. Yeomans, and R.W. Gray Opioid peptides and the control of human ingestive behaviour Neurosci Biobehav Rev 26 2002 713 728 (Pubitemid 35477576)
112. L.E. Hollister, K. Johnson, D. Boukhabza, and H.K. Gillespie Aversive effects of naltrexone in subjects not dependent on opiates Drug Alcohol Depend 8 1981 37 41 (Pubitemid 11004811)
113. H.A. Sternbach, W. Annitto, A.L. Pottash, and M.S. Gold Anorexic effects of naltrexone in man Lancet 1 1982 388 389 (Pubitemid 12214771)
114. C.A. Maggio, E. Presta, E.F. Bracco, J.R. Vasselli, H.R. Kissileff, and D.N. Pfohl et al. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men Brain Res Bull 14 1985 657 661 (Pubitemid 16239703)
115. R. Malcolm, P.M. O'Neil, J.D. Sexauer, F.E. Riddle, H.S. Currey, and C. Counts A controlled trial of naltrexone in obese humans Int J Obes 9 1985 347 353 (Pubitemid 16201361)
116. F.L. Greenway, E. Dunayevich, G. Tollefson, J. Erickson, M. Guttadauria, and K. Fujioka et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo J Clin Endocrinol Metab 94 2009 4898 4906
117. F.L. Greenway, M.J. Whitehouse, M. Guttadauria, J.W. Anderson, R.L. Atkinson, and K. Fujioka et al. Rational design of a combination medication for the treatment of obesity Obesity (Silver Spring, MD) 17 2009 30 39 (Pubitemid 50324544)
118. R.L. Atkinson, L.K. Berke, C.R. Drake, M.L. Bibbs, F.L. Williams, and D.L. Kaiser Effects of long-term therapy with naltrexone on body weight in obesity Clin Pharmacol Ther 38 1985 419 422 (Pubitemid 16250316)
119. J.A. Ascher, J.O. Cole, J.N. Colin, J.P. Feighner, R.M. Ferris, and H.C. Fibiger et al. Bupropion: a review of its mechanism of antidepressant activity J Clin Psychiatry 56 1995 395 401
120. K.F. Foley, K.P. DeSanty, and R.E. Kast Bupropion: pharmacology and therapeutic applications Expert Rev Neurother 6 2006 1249 1265 (Pubitemid 44580948)
121. Prescribing information: Wellbutrin (bupropion hydrochloride) tablets 2013 GlaxoSmithKline
122. K.M. Gadde, and G.L. Xiong Bupropion for weight reduction Expert Rev Neurother 7 2007 17 24 (Pubitemid 46105291)
123. G.G. Nomikos, G. Damsma, D. Wenkstern, and H.C. Fibiger Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum Neuropsychopharmacology 7 1992 7 14
124. M.F. Roitman, S. Wescott, J.J. Cone, M.P. McLane, and H.R. Wolfe Msi-1436 reduces acute food intake without affecting dopamine transporter activity Pharmacol Biochem Behav 97 2010 138 143
125. C.A. Paladini, S. Robinson, H. Morikawa, J.T. Williams, and R.D. Palmiter Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism Proc Natl Acad Sci U S A 100 2003 2866 2871 (Pubitemid 36297590)
126. Z.U. Khan, A. Gutierrez, R. Martin, A. Penafiel, A. Rivera, and A. De La Calle Differential regional and cellular distribution of dopamine d2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain J Comp Neurol 402 1998 353 371 (Pubitemid 28541684)
127. G.S. Fraley, and S. Ritter Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-d-glucose-induced neuropeptide y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus Endocrinology 144 2003 75 83 (Pubitemid 36076095)
128. H. Pijl Reduced dopaminergic tone in hypothalamic neural circuits: expression of a thrifty genotype underlying the metabolic syndrome Eur J Pharmacol 480 2003 125 131 (Pubitemid 37410365)
129. E.J. Nestler, and W.A. Carlezon Jr. The mesolimbic dopamine reward circuit in depression Biol Psychiatry 59 2006 1151 1159 (Pubitemid 44192421)
130. Y.L. Liu, I.P. Connoley, J. Harrison, D.J. Heal, and M.J. Stock Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors Eur J Pharmacol 452 2002 49 56 (Pubitemid 35248123)
131. Y.L. Liu, I.P. Connoley, D.J. Heal, and M.J. Stock Pharmacological characterisation of the thermogenic effect of bupropion Eur J Pharmacol 498 2004 219 225 (Pubitemid 39208082)
132. H. Hasegawa, R. Meeusen, S. Sarre, M. Diltoer, M.F. Piacentini, and Y. Michotte Acute dopamine/norepinephrine reuptake inhibition increases brain and core temperature in rats J Appl Physiol 99 2005 1397 1401 (Pubitemid 43014346)
133. S.K. Billes, and M.A. Cowley Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis Neuropsychopharmacology 33 2008 1287 1297 (Pubitemid 351521727)
134. S.K. Billes, and M.A. Cowley Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice Neuropsychopharmacology 32 2007 822 834 (Pubitemid 46426174)
135. M.R. Zarrindast, and T. Hosseini-Nia Anorectic and behavioural effects of bupropion Gen Pharmacol 19 1988 201 204
136. F.L. Wright, and R.J. Rodgers Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash Psychopharmacology (Berl) 228 2013 291 307
137. J.W. Anderson, F.L. Greenway, K. Fujioka, K.M. Gadde, J. McKenney, and P.M. O'Neil Bupropion sr enhances weight loss: a 48-week double-blind, placebo-controlled trial Obes Res 10 2002 633 641 (Pubitemid 135688262)
138. A.K. Jain, R.A. Kaplan, K.M. Gadde, T.A. Wadden, D.B. Allison, and E.R. Brewer et al. Bupropion SR vs Placebo for weight loss in obese patients with depressive symptoms Obes Res 10 2002 1049 1056 (Pubitemid 135688922)
139. K.M. Gadde, C.B. Parker, L.G. Maner, H.R. Wagner 2nd, E.J. Logue, and M.K. Drezner et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women Obes Res 9 2001 544 551 (Pubitemid 33610175)
140. N. Harto-Truax, W.C. Stern, L.L. Miller, T.L. Sato, and A.E. Cato Effects of bupropion on body weight J Clin Psychiatry 44 1983 183 186 (Pubitemid 13088863)
141. J.D. Griffith, J. Carranza, C. Griffith, L.L. Miller, and Bupropion Clinical assay for amphetamine-like abuse potential J Clin Psychiatry 44 1983 206 208 (Pubitemid 13088868)
142. P. Sinnayah, N. Wallingford, A. Evans, and M.A. Cowley Bupropion and naltrexone interact synergistically to decrease food intake in mice Presented at the North American association for the study of obesity annual scientific meeting New Orleans, LA 2007
143. S.R. Smith, K. Fujioka, A.K. Gupta, S.K. Billes, C. Burns, and D. Kim et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity Diabetes Obes Metab 15 2013 863 866
144. F.L. Greenway, K. Fujioka, R.A. Plodkowski, S. Mudaliar, M. Guttadauria, and J. Erickson et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (cor-i): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 376 2010 595 605
145. T.A. Wadden, J.P. Foreyt, G.D. Foster, J.O. Hill, S. Klein, and P.M. O'Neil et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the cor-bmod trial Obesity 19 2011 110 120
146. C.M. Apovian, L. Aronne, D. Rubino, C. Still, H. Wyatt, and C. Burns et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring, MD) 21 2013 935 943
147. P. Hollander, A.K. Gupta, R. Plodkowski, F. Greenway, H. Bays, and C. Burns et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes Diabetes Care 36 2013 4022 4029
148. C.S. Wilcox, N. Oskooilar, J.S. Erickson, S.K. Billes, B.B. Katz, and G. Tollefson et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects Addict Behav 35 2010 229 234
149. S.L. McElroy, A.I. Guerdjikova, D.D. Kim, C. Burns, R. Harris-Collazo, and R. Landbloom et al. Naltrexone/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study Prim Care Companion CNS Disord 2013 15
150. A. Flint, A. Raben, J.E. Blundell, and A. Astrup Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies Int J Obes Relat Metab Disord 24 2000 38 48 (Pubitemid 30098877)
151. A.J. Hill, C.F. Weaver, and J.E. Blundell Food craving, dietary restraint and mood Appetite 17 1991 187 197
152. K. Fujioka, B. Walsh, C. Burns, and P. Klassen Early improvement in control of eating is associated with long-term weight loss - integrated analysis of four phase 3 trials of combination naltrexone/bupropion treatment American Diabetes Association 73rd Scientific Session Chicago, IL 2013
153. M.A. White, B.L. Whisenhunt, D.A. Williamson, F.L. Greenway, and R.G. Netemeyer Development and validation of the food-craving inventory Obes Res 10 2002 107 114 (Pubitemid 135687498)
154. G.J. Wang, D. Tomasi, N.D. Volkow, R. Wang, F. Telang, and E.C. Caparelli et al. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues Int J Obes 2013 10.1038/ijo.2013.145
155. M. Michaelides, P.K. Thanos, N.D. Volkow, and G.J. Wang Translational neuroimaging in drug addiction and obesity ILAR J 53 2012 59 68
156. M.A. Cornier, S.S. Von Kaenel, D.H. Bessesen, and J.R. Tregellas Effects of overfeeding on the neuronal response to visual food cues Am J Clin Nutr 86 2007 965 971 (Pubitemid 47538297)
157. P.C. Fletcher, A. Napolitano, A. Skeggs, S.R. Miller, B. Delafont, and V.C. Cambridge et al. Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum J Neurosci 30 2010 14346 14355
158. M.A. Cornier, A.K. Salzberg, D.C. Endly, D.H. Bessesen, D.C. Rojas, and J.R. Tregellas The effects of overfeeding on the neuronal response to visual food cues in thin and reduced-obese individuals PLoS One 4 2009 e6310
159. P. Holzer Opioid receptors in the gastrointestinal tract Regul Pept 155 2009 11 17
160. C.J. Bailey, and R.C. Turner Metformin N Engl J Med 334 1996 574 579 (Pubitemid 126537875)
161. Clinicaltrials.Gov identifier: Nct01601704 Cardiovascular outcomes study of naltrexone SR/bupropion SR in overweight and obese subjects with cardiovascular risk factors (the light study) 2012 Orexigen Therapeutics
162. T.A. Wadden, S. Volger, A.G. Tsai, D.B. Sarwer, R.I. Berkowitz, and L.K. Diewald et al. Managing obesity in primary care practice: an overview with perspective from the power-up study Int J Obes (Lond) 37 Suppl. 1 2013 S3 S11
163. D.B. Sarwer, A. von Sydow Green, M.L. Vetter, and T.A. Wadden Behavior therapy for obesity: where are we now? Curr Opin Endocrinol Diab Obes 16 2009 347 352
164. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjostrom Xenical in the prevention of diabetes in obese subjects (xendos) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161 (Pubitemid 38196725)
165. R. Padwal, A. Kezouh, M. Levine, and M. Etminan Long-term persistence with orlistat and sibutramine in a population-based cohort Int J Obes (Lond) 31 2007 1567 1570 (Pubitemid 47482652)
166. C. Hampp, E.M. Kang, and V. Borders-Hemphill Use of prescription antiobesity drugs in the United States Pharmacotherapy 33 2013 1299 1307